期刊文献+

CA125、D-二聚体在卵巢癌中的应用价值 被引量:5

The Value of CA125 and D-dimer with Ovarian Cancer
暂未订购
导出
摘要 卵巢癌发病率在妇科恶性肿瘤中居第3位,而病死率却居首位。卵巢癌起病隐匿,早期缺乏典型临床表现,易发生腹腔内播散转移,70%的患者就诊时已属晚期。虽然目前卵巢癌可经肿瘤细胞减灭术辅以化疗得到有效治疗,但因其复发率较高,晚期患者5年存活率仅为30%左右。早期诊断、有效治疗、降低复发对卵巢癌的预后有重要影响。研究者致力于寻找指标,如CA125、D-二聚体,以应用于卵巢癌的早期诊断、疗效观察及预后评估。综述CA125、D-二聚体在卵巢癌中的应用价值。 Ovarian cancer is the third common cause of cancer-related mortality among women, but it is the leading cause of death from gynecologic cancers. More than 70% of the women are diagnosed at late stage disease. The reason for this is that the tumor, which develops from the ovarians located in the peritoneal cavity, may grow quite large and metastasize before it is diagnosed because of lack of symptoms. Moreover, it has a high recurrence rate even with optimal cytoreductive surgery and effective chemotherapy. So the 5-year overall survival rate for women diagnosed with late stage disease is only about 30%. Early diagnosis, effective treatment and reduce the recurrence of ovarian cancer have important impacts on prognosis. Researchers dedicated to finding indicators, such as CA125, D-dimer, which can be used in early diagnosis of ovarian cancer, treatment response monitoring and prognosis. In this paper, CA125 and D-dimer in the value of ovarian cancer start review.
作者 刘侃 张虹
出处 《国际妇产科学杂志》 CAS 2011年第4期297-301,共5页 Journal of International Obstetrics and Gynecology
关键词 卵巢肿瘤 CA-125抗原 诊断 预后 D-二聚体 Ovarian neoplasms CA-125 antigen Diagnosis Prognosis D-dimer
  • 相关文献

参考文献1

二级参考文献19

  • 1Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24: 484-490.
  • 2Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-1850.
  • 3Arklel YS. Thrombosis and cancer. Semin Oncol 2000; 27: 362-374.
  • 4Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency characteristic. Thromb Haemost 2002; 87: 575-579.
  • 5Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006; 119: 60-68.
  • 6King MB, Harmon KR. Unusual forms of pulmonary embolism. Clin Chest Med 1994; 15: 561-580.
  • 7Chan CK, Hutcheon MA, Hyland RH, Smith GJ, Patterson B J, Matthay RA. Pulmonary tumor embolism: A critical review of clinical, imaging, and hemodynamic features. J Thorac Imag 1987; 2: 4-14.
  • 8Roberts KE, Hamele-Bena D, Saqi A, Stein CA, Cole RP. Pulmonary tumor embolism: a review of the literature. Am J Med 2003; 115: 228-232.
  • 9Kucher N, Goldhaber SZ. Management of massive pulmonary embolism. Circulation 2005; 112: e28-e32.
  • 10Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombolic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-722.

共引文献19

同被引文献57

引证文献5

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部